Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 plus chemotherapy versus placebo plus chemotherapy for previously untreated advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
CTR20212351Phase 3Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Dec 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric cancer (GC) and gastroesophageal junction adenocarcinoma comparing SHR-1701 + oxaliplatin + capecitabine with Placebo + oxaliplatin + capecitabine (2 arms). Primary endpoints: Number and proportion of subjects with dose-limiting toxicity, Incidence and severity of adverse events and serious adverse events; vital signs, ECG, and laboratory abnormalities and 2 more. Started Dec 2021; status: active.
02
Drugs
retlirafusp alfa
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20212351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212351.